Competition

Dutch antitrust watchdog publishes additional notification requirements for healthcare mergers

Iradj Nazaryar

The Dutch Authority for Consumers and Markets (ACM) has published a new method of analysing product markets in merger investigations with respect to specialised medical care. In this context, the ACM requires merging hospitals and independent treatment centres to provide more detailed information in their merger notifications to the ACM. The starting point for the Read More

Coordination amongst member states on medicines’ prices supported by the European Commission

Nele De Backer

European Commissioner for Health and Food Safety, Vytenis Andriukaitis, said that the European Commission will support national competition authorities in their probes against excessive pricing practices in pharmaceutical markets. In addition, the European Commission will continue to monitor pharmaceutical markets itself, as part of its competition policy, and is ready to act against infringements of Read More

European Commission issues report on antitrust enforcement in the pharmaceutical sector

Dominc Long

A decade on from its inquiry into the pharmaceutical sector in 2009, on 28 January 2019 the European Commission (EC) issued a report providing an overview of antitrust law enforcement (antitrust and mergers) in the EU from 2009-2017 in the pharmaceutical sector. The report confirms that effective enforcement of EU antitrust rules in the sector Read More

Belgian consumer association announces potential complaint for abuse of dominance based on excessive pricing allegations

Francesca Miotto

Last week, a spokesperson for the Belgian consumer association Test Aankoop/Test Achats announced that the association is likely to lodge a complaint with the Belgian Competition Authority against the Italian pharmaceutical company Leadiant. Allegedly, Leadiant abused its dominant position in the market for chenodeoxycholic acid (CDCA), the active substance in the treatment of the rare Read More

Competition authorities debate the circumstances in which intervention against alleged excessive pricing practice in the pharmaceutical sector may be justified

Francesca Miotto

In recent years, consumer organisations have been monitoring the evolution of medicine prices in the EU and have, in some cases, called for the intervention of competition authorities to protect citizens’ rights to affordable healthcare. In the context of this resurgence of interest in excessive pricing in the pharmaceutical sector, on 28 November 2018, the Read More